Frasier Syndrome: Comprehensive Disease-Characteristics Report

Executive summary

Frasier syndrome (FS) is an ultra-rare, autosomal-dominant WT1 disorder, usually caused by heterozygous germline variants affecting the intron-9 alternative splice donor. Its defining clinical combination is progressive proteinuric glomerulopathy—usually steroid-resistant nephrotic syndrome (SRNS) with focal segmental glomerulosclerosis (FSGS)—and gonadal dysgenesis, especially in 46,XY individuals, with a clinically important risk of gonadoblastoma. Contemporary experts increasingly regard Frasier and Denys–Drash syndromes as overlapping ends of a continuous WT1-disorder spectrum rather than completely discrete entities. (shao2023frasiersyndromea pages 1-2, sambharia2022monogenicfocalsegmental pages 11-12, peer2024clinicalcharacterizationof pages 7-9)

The most important recent development is recognition of a wider and temporally variable WT1 phenotype. A 2024 Dutch national cohort found that all four individuals with intron-9 splice variants developed chronic kidney disease (CKD), with median onset at 15 years, while other WT1 variant classes could cause kidney failure as late as adulthood. This supports lifelong renal surveillance and full-gene testing rather than reliance on classical syndrome labels or hotspot-only sequencing. (peer2024clinicalcharacterizationof pages 1-2, peer2024clinicalcharacterizationof pages 2-4, peer2024clinicalcharacterizationof pages 7-9)

The following table provides a knowledge-base-oriented synopsis; broader WT1-spectrum statistics are identified as such rather than presented as Frasier-specific rates.

Table: Compact synthesis of high-confidence Frasier syndrome genetics, clinical features, mechanisms, management, quantitative evidence, ontology candidates, and major knowledge gaps. Broader WT1-spectrum statistics are explicitly distinguished from Frasier-specific observations.

1. Disease information

Definition and classification

FS is a Mendelian developmental and renal disorder caused by pathogenic germline WT1 variants. The classical phenotype comprises childhood-onset proteinuria progressing to CKD/ESKD, FSGS, 46,XY gonadal dysgenesis with female or atypical external genitalia, gonadal failure, and gonadoblastoma susceptibility. Less typical presentations occur in phenotypic males and 46,XX individuals. (shao2023frasiersyndromea pages 1-2, paul2021suspicionoffrasiers pages 4-7, kitsioutzeli2012sertolicelltumor pages 7-7)

Suggested identifiers are OMIM 136680 and ORPHA:347. A current MONDO identifier should be verified directly against the production MONDO release before ingestion; the retrieved primary literature did not state one. No dedicated ICD-10-CM code exists: coding ordinarily combines congenital gonadal-development, nephrotic/CKD, and genetic-condition codes. ICD-11 and MeSH similarly tend to represent the component phenotypes or broader WT1-related disorder rather than a uniquely granular FS entity.

Synonyms include Frasier syndrome, Frasier’s syndrome, WT1-related Frasier syndrome, and historically “46,XY male pseudohermaphroditism with progressive glomerulopathy.” The latter terminology is obsolete and potentially stigmatizing; 46,XY difference/disorder of sex development (DSD) or 46,XY gonadal dysgenesis is preferred.

Evidence is predominantly aggregated disease-level literature, retrospective WT1 cohorts, systematic case compilations, and individual case reports. It is not primarily derived from routine EHR population studies.

A useful exact abstract statement from Shao et al. (published 17 March 2023; DOI: https://doi.org/10.3390/children10030577) is: “Frasier syndrome (FS) is a rare inherited disorder characterized by gonadal dysgenesis and progressive nephropathy, resulting from mutations in the intron 9 splice donor site of the Wilms tumor 1 (WT1) gene.” (shao2023frasiersyndromea pages 1-2)

2. Etiology

Causal and genetic risk factors

The causal lesion is a heterozygous germline WT1 variant, classically at nucleotides +4 or +5 of intron 9. A recurrent example is NM_024426.6:c.1447+4C>T, historically IVS9+4C>T. A 2023 patient carried this variant; neither parent nor a sibling carried it, supporting a de novo event. The disorder is nevertheless autosomal dominant, so an affected individual has a theoretical 50% transmission probability, subject to reproductive capacity and variant-specific expression. (shao2023frasiersyndromea pages 2-4)

Variants outside the canonical intron-9 donor can produce overlapping phenotypes. Thus, a patient with WT1-associated FSGS and DSD should not be excluded merely because the genotype or presentation is nonclassical. The 2014 cohort found that 28% of mutation-positive patients initially appeared to have isolated sporadic SRNS and another 28% had extrarenal findings recognized only after genotype-directed examination. (lipska2014genotypephenotypeassociationsin pages 8-9)

Pathogenic FS variants are expected to be absent or exceptionally rare in population databases, but allele-level gnomAD frequency and ClinVar classification should be checked against the exact transcript and genome build. No reliable carrier-frequency, founder-effect, anticipation, or population-specific enrichment estimate is available.

Environmental, infectious, and protective factors

No toxin, infection, lifestyle, diet, occupation, or prenatal exposure has been shown to cause FS. Environmental factors may affect general CKD progression but are not established FS etiologies. No validated protective allele, modifier gene, protective lifestyle exposure, or disease-specific gene–environment interaction has been demonstrated. Likewise, no reproducible FS-specific epigenetic signature is established. These are evidence gaps, not evidence that modifiers cannot exist.

3. Phenotypes

Renal manifestations

The usual earliest recognized renal abnormality is persistent proteinuria in childhood, sometimes accompanied by edema and hypertension. Historical compilations place onset commonly between ages 2 and 10, followed by steroid-resistant nephrotic syndrome, declining glomerular filtration, CKD, and ESKD during adolescence or early adulthood. Severity and timing are variable. (paul2021suspicionoffrasiers pages 4-7)

Renal biopsy usually shows FSGS; diffuse mesangial sclerosis is possible but is more typical of early, severe WT1 disease classically labeled Denys–Drash. In the broader 2024 WT1 cohort, FSGS was confirmed in 11 patients at a median age of four years, and all ten evaluable FSGS patients progressed to kidney failure. Those figures are not FS-specific. (peer2024clinicalcharacterizationof pages 2-4, peer2024clinicalcharacterizationof pages 4-6, peer2024clinicalcharacterizationof pages 6-7)

Suggested HPO concepts include proteinuria, nephrotic syndrome, steroid-resistant nephrotic syndrome, FSGS, hypertension, renal insufficiency, CKD, and ESKD. Exact HPO identifiers should be resolved against the current HPO release.

Gonadal, genital, and endocrine manifestations

The classical patient has a 46,XY karyotype, female external genitalia, bilateral streak or dysgenetic gonads, absent or impaired testicular differentiation, and primary gonadal failure. Delayed or absent puberty, absent secondary sexual characteristics, primary amenorrhea, and hypergonadotropic hypogonadism may be the presenting features. Phenotypic males can have cryptorchidism, hypospadias, micropenis, or ambiguous genitalia. (shao2023frasiersyndromea pages 2-4, paul2021suspicionoffrasiers pages 4-7, kitsioutzeli2012sertolicelltumor pages 7-7)

The 2023 case is clinically important because a 15-year-old phenotypic female presented first with delayed puberty; investigation then disclosed 46,XY karyotype, c.1447+4C>T, proteinuria, renal insufficiency, and FSGS. This supports karyotyping and renal evaluation in otherwise unexplained delayed puberty. (shao2023frasiersyndromea pages 2-4, shao2023frasiersyndromea pages 1-2)

Suggested HPO concepts include 46,XY sex reversal, complete/partial gonadal dysgenesis, streak gonad, cryptorchidism, hypospadias, female external genitalia in a 46,XY individual, delayed puberty, primary amenorrhea, and hypergonadotropic hypogonadism.

Tumors

Dysgenetic gonads containing Y-chromosome material have substantial gonadoblastoma risk, with possible progression or coexistence with dysgerminoma. Tumors can occur in childhood, adolescence, or adulthood. In a 2014 WT1 cohort, three of nine patients with sex reversal developed gonadoblastoma; the 2024 cohort reported four gonadoblastomas, including one intron-9 patient at age 23, and intratubular germ-cell neoplasia in another intron-9 patient at age 15. These small, ascertainment-biased data should not be treated as precise penetrance estimates. (lipska2014genotypephenotypeassociationsin pages 8-9, peer2024clinicalcharacterizationof pages 4-6)

Wilms tumor belongs to the broader WT1 spectrum but appears less characteristic of classical intron-9 FS than of truncating/deletion or zinc-finger missense disorders. In the 2024 cohort, none of four intron-9 cases had Wilms tumor, whereas the overall WT1 cohort rate was 26/43; ascertainment substantially influenced that overall figure. (peer2024clinicalcharacterizationof pages 2-4)

Quality of life

No FS-specific EQ-5D, SF-36, or PROMIS study was identified. Likely burdens include chronic medication and monitoring, nephrotic edema, hypertension, dialysis, transplantation, infertility, gonadectomy, hormone replacement, tumor anxiety, disclosure of chromosomal findings, and psychosocial issues surrounding sex development. These require individualized, multidisciplinary and developmentally appropriate support.

4. Genetic and molecular information

WT1, located at 11p13, encodes a zinc-finger transcriptional regulator essential to kidney, podocyte, and gonadal development. Classical FS is produced by germline heterozygous splice-region variants rather than somatic variants. Somatic WT1 alterations may occur in tumors but do not by themselves establish inherited FS. (paul2021suspicionoffrasiers pages 4-7, shao2023frasiersyndromea pages 2-4)

The normal kidney expresses WT1 isoforms with and without a three-amino-acid lysine-threonine-serine insertion. The normal +KTS:−KTS ratio is approximately 2:1. Classical intron-9 variants impair the +KTS splice donor and shift the ratio toward approximately 1:2, rather than simply eliminating all WT1 protein. (paul2021suspicionoffrasiers pages 4-7, peer2024clinicalcharacterizationof pages 2-4)

The recurrent c.1447+4C>T variant is a splice-region variant predicted to disrupt donor-site recognition. Pathogenicity assessment should include phenotype concordance, segregation/de novo evidence, population absence, computational splice prediction, and—where available—RNA evidence under ACMG/AMP criteria. The precise functional label is altered isoform dosage/splicing; describing every intron-9 FS allele as simple haploinsufficiency would be incomplete.

No validated modifier gene, disease-specific methylation pattern, recurrent large chromosomal abnormality, or causal structural variant defines classical FS. Larger 11p13 deletions instead suggest WAGR-spectrum disease. Phenotypic variability among people carrying similar WT1 variants indicates that unknown modifiers probably exist, but this remains inference. (peer2024clinicalcharacterizationof pages 7-9)

5. Environmental information

Environmental toxins, radiation, pollution, smoking, diet, alcohol, exercise, occupation, and infectious agents are not established causes or triggers. Standard kidney-protective measures—blood-pressure control, avoidance of nephrotoxins, and management of cardiovascular risk—are clinically rational but do not prevent the inherited developmental defect.

6. Mechanism and pathophysiology

Ordered causal chain

1. A heterozygous germline WT1 intron-9 splice-region variant leads to defective alternative splice-site use.
2. Defective splicing results in reduced production of +KTS transcripts and reversal of the normal +KTS:−KTS balance. (paul2021suspicionoffrasiers pages 4-7, peer2024clinicalcharacterizationof pages 2-4)
3. Altered WT1 isoform dosage leads to dysregulated transcriptional/RNA-regulatory programs in WT1-dependent developmental and adult cell populations; many specific downstream targets in human FS remain incompletely demonstrated.
4. Renal branch: disturbed WT1 activity in podocytes results in defective podocyte differentiation/maintenance and glomerular filtration-barrier instability.
5. Podocyte injury and loss lead to proteinuria, foot-process dysfunction, segmental sclerosis/FSGS, nephrotic syndrome, progressive nephron loss, CKD, and ESKD. (sambharia2022monogenicfocalsegmental pages 11-12, peer2024clinicalcharacterizationof pages 6-7)
6. Gonadal branch: disturbed WT1-dependent gonadal and mesonephric development leads to impaired testicular differentiation in susceptible 46,XY embryos.
7. Gonadal dysgenesis results in female or atypical external genital development, streak gonads, gonadal hormone deficiency, delayed puberty, amenorrhea, and infertility.
8. Persistence of dysgenetic gonadal tissue containing Y-chromosome material increases survival of developmentally abnormal germ cells and leads to gonadoblastoma risk; detailed intermediate molecular steps are partly inferred from DSD tumor biology. (lipska2014genotypephenotypeassociationsin pages 8-9, peer2024clinicalcharacterizationof pages 4-6)

The initiating splice defect is upstream; podocyte loss, sclerosis, endocrine failure, and neoplasia are downstream. No primary metabolic enzyme deficiency, ion-channel defect, infection, or systemic autoimmune process is implicated. Inflammation and fibrosis are secondary consequences of chronic tissue injury rather than the initiating lesion.

Suggested GO processes include RNA splicing, regulation of transcription by RNA polymerase II, metanephric glomerulus development, podocyte differentiation, maintenance of glomerular filtration barrier, gonad development, and sex differentiation. Suggested cell types include podocyte, gonadal somatic/supporting cell, Sertoli-lineage cell, and primordial germ cell; exact GO/CL identifiers should be validated.

No robust FS-specific single-cell, spatial-transcriptomic, proteomic, metabolomic, lipidomic, or CRISPR-screen signature was identified. These are priority research gaps.

7. Anatomical structures affected

Primary organs are the kidneys and gonads. In the kidney, the glomerulus—particularly visceral epithelial cells/podocytes—is the principal target; secondary tubulointerstitial fibrosis and whole-kidney failure follow progressive glomerular injury. In the reproductive system, dysgenetic/streak gonads and mesonephric-derived structures are affected; external genital anatomy varies. (shao2023frasiersyndromea pages 2-4, peer2024clinicalcharacterizationof pages 6-7)

Suggested anatomy terms are kidney, renal glomerulus, glomerular visceral epithelium, gonad, testis, streak gonad, uterus, and external genitalia. Suggested Cell Ontology term: podocyte. At the subcellular level WT1 primarily acts in the nucleus through its zinc-finger regulatory domains, while +KTS isoforms also have RNA-associated functions. Bilaterality is typical for gonadal dysgenesis and diffuse genetic nephropathy, although histologic sclerosis is segmental and tumor involvement may be unilateral or bilateral.

8. Temporal development

The gonadal-development lesion is prenatal/congenital, although it may remain clinically unsuspected until pubertal failure. Renal disease is generally insidious and progressive: childhood proteinuria → SRNS/FSGS → CKD → ESKD, often in the second decade, but onset and progression vary. Classical FS tends to progress more slowly than Denys–Drash syndrome. (shao2023frasiersyndromea pages 1-2, sambharia2022monogenicfocalsegmental pages 11-12)

In the 2024 national cohort, all four intron-9 patients developed CKD at a median age of 15 years. This is stronger recent evidence for later onset than older descriptions, but the subgroup is very small. Lifelong surveillance remains appropriate because WT1-associated kidney failure may occur well beyond childhood. (peer2024clinicalcharacterizationof pages 2-4, peer2024clinicalcharacterizationof pages 7-9)

There is no spontaneous remission of the genetic lesion. Proteinuria may be attenuated symptomatically, but established sclerosis is usually progressive. Critical intervention windows are: early genetic diagnosis before unnecessary immunosuppression; gonadal evaluation before neoplasia; endocrine planning before or during puberty; and CKD care before irreversible complications.

9. Inheritance and population

Inheritance is autosomal dominant, commonly arising de novo. Penetrance is high for some WT1-associated manifestations but is not precisely quantified for FS; expressivity is clearly variable. No anticipation is recognized. Parental germline mosaicism is theoretically possible even when blood testing is negative, so recurrence risk is low but not absolutely zero after an apparently de novo finding.

No valid population prevalence or annual incidence per 100,000 is available. No consistent geographic, ancestry, founder, or consanguinity association is established. WT1 variants accounted for approximately 6% of SRNS in one intensively studied cohort, but this is neither population prevalence nor an FS-specific percentage. (lipska2014genotypephenotypeassociationsin pages 8-9)

A conventional male:female ratio is biologically misleading because chromosomal sex, gonadal development, external phenotype, and gender identity can differ. Most classical reports concern 46,XY individuals with a female phenotype, but phenotypic males and 46,XX cases occur.

10. Diagnostics

Clinical evaluation

Evaluation should include urinalysis and urine protein quantification, serum creatinine/eGFR, albumin, electrolytes, blood pressure, renal ultrasonography, pubertal staging, LH/FSH and sex steroids when indicated, pelvic/gonadal ultrasonography or MRI, and chromosome analysis. Tumor-marker testing is guided by the gonadal lesion and specialist team; normal markers do not exclude gonadoblastoma.

Kidney biopsy may show FSGS and can characterize unexplained SRNS, but molecular diagnosis is decisive and biopsy is not required when the clinical-genetic diagnosis is clear. Gonadal pathology after surgery should assess gonadoblastoma, dysgerminoma, and germ-cell neoplasia.

Genetic testing strategy

Preferred testing is a comprehensive nephrotic-syndrome/DSD panel including WT1 or full WT1 sequencing with intron-exon boundaries plus deletion/duplication analysis. Targeted testing for c.1447+4C>T and other intron-9 donor variants is efficient when the phenotype is classic, but a negative hotspot test should be followed by full-gene analysis. WES or WGS is useful for atypical or panel-negative disease; WGS can better interrogate noncoding/structural variation. CMA or karyotype is appropriate when a larger 11p13 deletion or sex-chromosome discordance is suspected. FISH is situational. Mitochondrial and repeat-expansion testing are not routinely relevant. (peer2024clinicalcharacterizationof pages 2-4, peer2024clinicalcharacterizationof pages 7-9)

RNA analysis can demonstrate abnormal splicing and help resolve a VUS, but it is not yet routine. No validated proteomic, metabolomic, epigenomic, or liquid-biopsy diagnostic test exists.

Diagnostic clues and differential diagnosis

Genetic testing and karyotyping should be prioritized in: (1) childhood SRNS/FSGS with atypical genitalia; (2) a phenotypic female with SRNS, CKD, delayed puberty, or primary amenorrhea; and (3) unexplained CKD with cryptorchidism or hypospadias. (shao2023frasiersyndromea pages 1-2, drayer2022spectrumofclinical pages 10-11)

Differentials include Denys–Drash syndrome/other WT1 disorder, WAGR syndrome, isolated genetic FSGS (e.g., NPHS1, NPHS2, LAMB2, PLCE1), complete androgen insensitivity, Swyer syndrome from other genes, 5α-reductase or 17β-HSD deficiency, NR5A1-related DSD, and Turner syndrome in a phenotypic female with pubertal failure. Denys–Drash usually has earlier, faster nephropathy, often DMS, and greater Wilms-tumor association; however, overlap is substantial and genotype should supersede rigid clinical labels. (shao2023frasiersyndromea pages 2-4, roca2009evolutivestudyof pages 5-6)

Population newborn screening is not available. Cascade testing should be offered after a familial variant is identified.

11. Outcome and prognosis

Renal prognosis without transplantation is poor: proteinuria and FSGS generally progress to ESKD. Frasier-specific five- or ten-year survival and life-expectancy estimates are unavailable. Mortality depends principally on renal failure, cardiovascular/dialysis complications, tumor development, and access to transplantation.

Kidney transplantation is effective because the molecular lesion is intrinsic to the native kidney; recurrence of genetic FSGS in the allograft is expected to be negligible. In a broader nine-child WT1 series, all underwent transplantation at a median age of five years; during median nine-year follow-up, two grafts were lost after seven and ten years and no post-transplant malignancy was observed. These outcomes cannot be assumed to represent FS alone. (drayer2022spectrumofclinical pages 1-2)

A 2021 suspected case with severe untreated ESKD died after dialysis-associated cardiac arrest, illustrating the consequences of late recognition, but molecular confirmation was absent. (paul2021suspicionoffrasiers pages 1-4)

No validated FS-specific prognostic biomarker exists beyond genotype class, age/onset of proteinuria, kidney function trajectory, renal histology, and gonadal status. The 2024 cohort supports variant class as a broad predictor but also documents substantial within-class variability. (peer2024clinicalcharacterizationof pages 1-2, peer2024clinicalcharacterizationof pages 7-9)

12. Treatment

There is no approved disease-modifying or splice-correcting therapy.

Renal care: ACE inhibition or angiotensin-receptor blockade may reduce proteinuria and control hypertension; standard CKD care includes salt/fluid management, anemia and mineral-bone treatment, vaccination, cardiovascular-risk control, and avoidance of nephrotoxins. Because genetic WT1 podocytopathy is usually immunosuppression-resistant, prolonged corticosteroid, calcineurin-inhibitor, or other immunosuppressive trials should generally be avoided once a causal diagnosis is established. (drayer2022spectrumofclinical pages 1-2, drayer2022spectrumofclinical pages 10-11)

Kidney replacement: dialysis is used for ESKD, followed by kidney transplantation when feasible. Disease recurrence in the graft is unlikely. Native nephrectomy is individualized for severe hypertension, protein loss, tumor, or surgical considerations; prophylactic nephrectomy solely for FS is not supported by consensus. (drayer2022spectrumofclinical pages 10-11)

Gonadal management: dysgenetic gonads containing Y-chromosome material should be evaluated promptly by a multidisciplinary DSD/tumor team. Prophylactic bilateral gonadectomy is commonly recommended because surveillance cannot reliably exclude microscopic gonadoblastoma. Timing should balance malignancy risk, anatomy, hormonal function, age, assent/consent, fertility implications, and patient preferences. (sambharia2022monogenicfocalsegmental pages 11-12, lipska2014genotypephenotypeassociationsin pages 8-9)

Endocrine and psychosocial care: pubertal induction or maintenance with individualized sex-steroid replacement is used after gonadectomy or for gonadal failure. Bone health, fertility counseling, sexual health, gender identity, and psychological support are integral. A 2023 patient underwent bilateral gonadectomy but declined hormone therapy, demonstrating that real-world management requires informed shared decision-making. (shao2023frasiersyndromea pages 2-4)

Suggested NCIT intervention concepts include genetic testing, gonadectomy, hormone-replacement therapy, ACE inhibitor therapy, hemodialysis, and kidney transplantation; identifiers should be normalized against the current NCIt release. No FS-specific pharmacogenomic guidance is available.

A completed observational registry, NCT01252901, enrolled 52 people with WT1-associated diseases. No FS-specific interventional, gene-therapy, RNA-therapy, cell-therapy, or CRISPR trial was identified. Thus, no controlled response rates or FS-specific adverse-event statistics are available.

13. Prevention

The spontaneous de novo occurrence of many variants means primary prevention is generally impossible. Genetic counseling, reproductive options—including targeted prenatal diagnosis and preimplantation genetic testing for a known familial variant—can reduce recurrence according to individual preferences.

Secondary prevention comprises early detection: cascade testing, chromosome analysis in clinically suspicious phenotypic females, early WT1 testing in SRNS/FSGS, renal surveillance, and prompt gonadal assessment. Tertiary prevention includes RAAS blockade and CKD management, avoidance of ineffective immunosuppression/nephrotoxins, timely gonadectomy to prevent gonadal malignancy, hormone replacement where appropriate, and transplantation before severe ESKD complications. No vaccine, antimicrobial prophylaxis, dietary regimen, or environmental intervention prevents FS itself.

14. Other species and natural disease

No established naturally occurring veterinary syndrome exactly equivalent to human FS was identified. Therefore, breed associations, VBO mappings, veterinary prevalence, zoonotic potential, and cross-species transmission are not applicable. The disease is genetic and noncommunicable.

The WT1 developmental program is evolutionarily conserved, making vertebrate models informative. Relevant taxonomy includes Homo sapiens (NCBI Taxon 9606) and Mus musculus (Taxon 10090). Ortholog identifiers should be imported directly from NCBI Gene/Alliance releases rather than inferred from the literature.

15. Model organisms and experimental systems

The strongest disease-mechanism model is the mouse with engineered reduction or loss of the +KTS isoform. Heterozygous reduction of +KTS produces glomerulosclerosis, while homozygous absence causes complete XY sex reversal. This reproduces the two principal human mechanistic branches and strongly supports causal involvement of isoform imbalance. (sambharia2022monogenicfocalsegmental pages 11-12)

Limitations are important: engineered mice do not reproduce the full range of human renal timing, gonadoblastoma penetrance, tumor histology, endocrine management, fertility, or psychosocial outcomes. Podocyte cultures, patient-derived cells, iPSCs, and kidney/gonadal organoids could test variant-specific splicing and downstream programs, but no validated FS-specific organoid or high-throughput therapeutic platform was identified in the retrieved evidence.

Evidence appraisal and priorities

The evidence base is constrained by ultra-rarity, inconsistent historical terminology, case-report enrichment, and mixing of FS with broader WT1 disorders. The 2024 national cohort is authoritative for the modern spectrum concept but includes only four intron-9 cases and is clinically ascertained. Its key conclusion—quoted from the article—is: “Therefore, life-long surveillance of kidney function is recommended.” (peer2024clinicalcharacterizationof pages 1-2, peer2024clinicalcharacterizationof pages 7-9)

Research priorities are prospective international natural-history cohorts; standardized genotype, karyotype and gonadal-pathology reporting; age-specific tumor-risk estimation; patient-reported outcomes; fertility and endocrine outcomes; single-cell studies of human podocyte and gonadal development; and variant-specific RNA/splice-correction strategies. Until those data emerge, early molecular diagnosis, multidisciplinary DSD care, gonadal tumor prevention, and planned renal replacement remain the principal real-world interventions.

References

1. (shao2023frasiersyndromea pages 1-2): Qing Shao, Xinglei Xie, Jia Geng, Xiaoling Yang, Wei Li, and Yuwei Zhang. Frasier syndrome: a 15-year-old phenotypically female adolescent presenting with delayed puberty and nephropathy. Mar 2023. URL: https://doi.org/10.3390/children10030577, doi:10.3390/children10030577. This article has 6 citations.

2. (sambharia2022monogenicfocalsegmental pages 11-12): Meenakshi Sambharia, Prerna Rastogi, and Christie P. Thomas. Monogenic focal segmental glomerulosclerosis: a conceptual framework for identification and management of a heterogeneous disease. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 190:377-398, Jul 2022. URL: https://doi.org/10.1002/ajmg.c.31990, doi:10.1002/ajmg.c.31990. This article has 35 citations.

3. (peer2024clinicalcharacterizationof pages 7-9): Sophie E. van Peer, Roland P. Kuiper, Janna A. Hol, Sanne Egging, Bert van der Zwaag, Marc R. Lilien, M. Paola Lombardi, Marry M. van den Heuvel-Eibrink, and Marjolijn C.J. Jongmans. Clinical characterization of a national cohort of patients with germline wt1 variants including late-onset phenotypes. Dec 2024. URL: https://doi.org/10.1016/j.ekir.2024.09.007, doi:10.1016/j.ekir.2024.09.007. This article has 8 citations and is from a peer-reviewed journal.

4. (peer2024clinicalcharacterizationof pages 1-2): Sophie E. van Peer, Roland P. Kuiper, Janna A. Hol, Sanne Egging, Bert van der Zwaag, Marc R. Lilien, M. Paola Lombardi, Marry M. van den Heuvel-Eibrink, and Marjolijn C.J. Jongmans. Clinical characterization of a national cohort of patients with germline wt1 variants including late-onset phenotypes. Dec 2024. URL: https://doi.org/10.1016/j.ekir.2024.09.007, doi:10.1016/j.ekir.2024.09.007. This article has 8 citations and is from a peer-reviewed journal.

5. (peer2024clinicalcharacterizationof pages 2-4): Sophie E. van Peer, Roland P. Kuiper, Janna A. Hol, Sanne Egging, Bert van der Zwaag, Marc R. Lilien, M. Paola Lombardi, Marry M. van den Heuvel-Eibrink, and Marjolijn C.J. Jongmans. Clinical characterization of a national cohort of patients with germline wt1 variants including late-onset phenotypes. Dec 2024. URL: https://doi.org/10.1016/j.ekir.2024.09.007, doi:10.1016/j.ekir.2024.09.007. This article has 8 citations and is from a peer-reviewed journal.

6. (shao2023frasiersyndromea pages 2-4): Qing Shao, Xinglei Xie, Jia Geng, Xiaoling Yang, Wei Li, and Yuwei Zhang. Frasier syndrome: a 15-year-old phenotypically female adolescent presenting with delayed puberty and nephropathy. Mar 2023. URL: https://doi.org/10.3390/children10030577, doi:10.3390/children10030577. This article has 6 citations.

7. (paul2021suspicionoffrasiers pages 4-7): Axler JEAN PAUL, Dieuguens LOUIS, Ansly Jefferson DESRAVINES, Raema Mimrod JEAN, Alfadler JEAN BAPTISTE, Jean Henold BUTEAU, and Wislet ANDRE. Suspicion of frasier's syndrome in the nephrology unit of the internal medicine department of the hueh: case study and review of the literature. Jun 2021. URL: https://doi.org/10.21203/rs.3.rs-622151/v1, doi:10.21203/rs.3.rs-622151/v1. This article has 0 citations.

8. (peer2024clinicalcharacterizationof pages 4-6): Sophie E. van Peer, Roland P. Kuiper, Janna A. Hol, Sanne Egging, Bert van der Zwaag, Marc R. Lilien, M. Paola Lombardi, Marry M. van den Heuvel-Eibrink, and Marjolijn C.J. Jongmans. Clinical characterization of a national cohort of patients with germline wt1 variants including late-onset phenotypes. Dec 2024. URL: https://doi.org/10.1016/j.ekir.2024.09.007, doi:10.1016/j.ekir.2024.09.007. This article has 8 citations and is from a peer-reviewed journal.

9. (peer2024clinicalcharacterizationof pages 6-7): Sophie E. van Peer, Roland P. Kuiper, Janna A. Hol, Sanne Egging, Bert van der Zwaag, Marc R. Lilien, M. Paola Lombardi, Marry M. van den Heuvel-Eibrink, and Marjolijn C.J. Jongmans. Clinical characterization of a national cohort of patients with germline wt1 variants including late-onset phenotypes. Dec 2024. URL: https://doi.org/10.1016/j.ekir.2024.09.007, doi:10.1016/j.ekir.2024.09.007. This article has 8 citations and is from a peer-reviewed journal.

10. (drayer2022spectrumofclinical pages 6-8): Patricia Arroyo-Parejo Drayer, Wacharee Seeherunvong, Chryso P. Katsoufis, Marissa J. DeFreitas, Tossaporn Seeherunvong, Jayanthi Chandar, and Carolyn L. Abitbol. Spectrum of clinical manifestations in children with wt1 mutation: case series and literature review. Frontiers in Pediatrics, Apr 2022. URL: https://doi.org/10.3389/fped.2022.847295, doi:10.3389/fped.2022.847295. This article has 24 citations.

11. (lipska2014genotypephenotypeassociationsin pages 8-9): Beata S. Lipska, Bruno Ranchin, Paraskevas Iatropoulos, Jutta Gellermann, Anette Melk, Fatih Ozaltin, Gianluca Caridi, Tomas Seeman, Kalman Tory, Augustina Jankauskiene, Aleksandra Zurowska, Maria Szczepanska, Anna Wasilewska, Jerome Harambat, Agnes Trautmann, Amira Peco-Antic, Halina Borzecka, Anna Moczulska, Bassam Saeed, Radovan Bogdanovic, Mukaddes Kalyoncu, Eva Simkova, Ozlem Erdogan, Kristina Vrljicak, Ana Teixeira, Marta Azocar, and Franz Schaefer. Genotype-phenotype associations in wt1 glomerulopathy. Kidney international, 85 5:1169-78, May 2014. URL: https://doi.org/10.1038/ki.2013.519, doi:10.1038/ki.2013.519. This article has 204 citations and is from a highest quality peer-reviewed journal.

12. (drayer2022spectrumofclinical pages 10-11): Patricia Arroyo-Parejo Drayer, Wacharee Seeherunvong, Chryso P. Katsoufis, Marissa J. DeFreitas, Tossaporn Seeherunvong, Jayanthi Chandar, and Carolyn L. Abitbol. Spectrum of clinical manifestations in children with wt1 mutation: case series and literature review. Frontiers in Pediatrics, Apr 2022. URL: https://doi.org/10.3389/fped.2022.847295, doi:10.3389/fped.2022.847295. This article has 24 citations.

13. (drayer2022spectrumofclinical pages 1-2): Patricia Arroyo-Parejo Drayer, Wacharee Seeherunvong, Chryso P. Katsoufis, Marissa J. DeFreitas, Tossaporn Seeherunvong, Jayanthi Chandar, and Carolyn L. Abitbol. Spectrum of clinical manifestations in children with wt1 mutation: case series and literature review. Frontiers in Pediatrics, Apr 2022. URL: https://doi.org/10.3389/fped.2022.847295, doi:10.3389/fped.2022.847295. This article has 24 citations.

14. (kitsioutzeli2012sertolicelltumor pages 7-7): Sophia Kitsiou-Tzeli, Maria Deligiorgi, Sophia Malaktari-Skarantavou, Charalampos Vlachopoulos, Spyridon Megremis, Irene Fylaktou, Joanne Traeger-Synodinos, Christina Kanaka-Gantenbein, Christodoulos Stefanadis, and Emmanuel Kanavakis. Sertoli cell tumor and gonadoblastoma in an untreated 29-year-old 46,xy phenotypic male with frasier syndrome carrying a wt1 ivs9+4c>t mutation. Hormones, 11:361-367, Jul 2012. URL: https://doi.org/10.14310/horm.2002.1366, doi:10.14310/horm.2002.1366. This article has 13 citations and is from a peer-reviewed journal.

15. (roca2009evolutivestudyof pages 5-6): Ana Pilar Nso Roca, Antonia Peña Carrión, Marta Benito Gutiérrez, Carmen García Meseguer, Araceli García Pose, and Mercedes Navarro. Evolutive study of children with diffuse mesangial sclerosis. Pediatric Nephrology, 24:1013-1019, May 2009. URL: https://doi.org/10.1007/s00467-008-1063-z, doi:10.1007/s00467-008-1063-z. This article has 32 citations and is from a domain leading peer-reviewed journal.

16. (paul2021suspicionoffrasiers pages 1-4): Axler JEAN PAUL, Dieuguens LOUIS, Ansly Jefferson DESRAVINES, Raema Mimrod JEAN, Alfadler JEAN BAPTISTE, Jean Henold BUTEAU, and Wislet ANDRE. Suspicion of frasier's syndrome in the nephrology unit of the internal medicine department of the hueh: case study and review of the literature. Jun 2021. URL: https://doi.org/10.21203/rs.3.rs-622151/v1, doi:10.21203/rs.3.rs-622151/v1. This article has 0 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, OMIM, Taxon.

No term could be looked up either way, so nothing here was confirmed or contradicted.